No Appetite on GLP-1: The Meals That Quietly Disappear

Appetite falling is what these medicines are described as doing — on the weight-management labels it is the mechanism, not a side effect. What no label covers is the meal that disappears entirely. Eat by the clock, notice which meal goes first, and keep the fluids going.

A practical article about eating when appetite is gone, not medical advice. For anything about your medication, appetite or nutrition, ask your prescriber or pharmacist.

By Ada Serra. Editor: Sezen Soykut.

---

Key takeaways

• On the weight-management product information, reduced appetite is not a side effect. It is how the medicine is described as working.
• When intake falls far enough, more than protein goes short: in one peer-reviewed study, fewer than one in ten participants met the recommended intakes for protein, fibre, vitamin D, calcium and potassium.
• With the hunger signal gone, the clock has to do its job. Anchor food to a time, or to something that already happens.
• No label states a number of missed meals. It states a fluid warning — that is the part to raise with your prescriber.

---

The appetite drop is in the label, just not where you are looking

The explanation is not in the side-effect table. On the European product information for semaglutide at weight-management doses, "decreased appetite" does not appear in the adverse-reaction list at all [1]. It sits in the pharmacology section, where the medicine's action is described: semaglutide "reduces appetite by increasing feelings of fullness and satiety", while lowering hunger [1]. The liraglutide 3.0 mg document sets out its own mechanism in the same place [3].

One catch if you search this yourself: the term does appear in an adverse-reaction table on the tirzepatide product information, footnoted to restrict that row to patients with type 2 diabetes [4]. Read the footnote, not the column.

So what is happening to you is the described action of the medicine, not a malfunction. What no label covers is the version that takes a whole meal with it.

A meal you skipped and a meal you never logged

A skipped meal is a decision. This usually is not one: it is 9 p.m., nothing has happened since breakfast, and the realisation arrives after the fact.

Separate two things that look the same in a diary — the meal that did not happen, and the meal that happened standing at the counter and never got written down. Only the first is about appetite. Then notice which meal goes first, whether it is always the same one, and whether fluids kept going when food did not.

What goes short is wider than protein

In 387 adults using weekly GLP-1 or dual GIP/GLP-1 treatment, studied in the Journal of Translational Medicine this year, fewer than one in ten met the recommended intakes — and not only for protein. Fibre, vitamin D, calcium and potassium sat in the same position [2].

Read it narrowly. Participants were recruited online through support groups, kept diaries over two days and had no comparison group; the authors name under-reporting among their own limitations [2]. It is not a portrait of a typical person on these medicines. What it gives you is the shape of the problem: when the total falls far enough, it is rarely one nutrient that goes missing. The muscle side has its own guide, preventing muscle loss on GLP-1s.

When the signal stops arriving, the clock has to do the job

Hunger used to handle the scheduling. With it gone, the ordinary substitutes are a fixed time or an existing habit — food attached to the end of work, the school run, the kettle going on. Unappetising, and reliable.

When volume is the limit, the unit changes too: what fits is smaller and more often than the dinner you used to cook. Treat that as the normal shape of a day.

Appetite returns unevenly — present some days, absent others, often in a window that does not match your old mealtimes. Plan around the window you have. The week has a shape as well: in that same study, weekday intake ran about 170 kcal above weekend intake [2], so it is worth knowing which of your own days are the thin ones. What to put in that window is covered in what to eat on Ozempic and Wegovy.

Where the line actually is

There is no number here, and be wary of anyone who offers one: no product information for these medicines states a threshold — days without eating, meals missed — at which something is wrong.

What the labels do state is a fluid warning. The semaglutide document asks that patients be advised of "the potential risk of dehydration" in relation to gastrointestinal side effects, and take precautions to avoid fluid depletion [1]. The liraglutide document carries the same instruction [3]. The tirzepatide one adds that this should particularly be considered in older people, who may be more susceptible to those complications [4].

Meals disappearing for days at a time, or fluids not staying down, is the point to tell whoever prescribed it — the leaflet itself tells you to talk to your doctor if you have questions or concerns about losing fluids [1], and that conversation is theirs to have with you rather than yours to work out alone. Why fluids get harder in the first place is covered in drinking enough on GLP-1.

The blank is information

Logging a meal you did not eat feels pointless. It is the opposite. One blank is a bad day; the same blank in the same slot four times in a week is a pattern, and a pattern is the only version of this anyone else can see. Nobody can read your appetite. They can read a fortnight of dinners that did not happen. The water intake calculator gives you a rough daily figure to aim at.

---

Sources

1. European Medicines Agency. Wegovy (semaglutide) — Summary of Product Characteristics and Package Leaflet, Annex I and Annex IIIB. First authorisation 06 January 2022. Sections 4.4, 4.8 and 5.1. Retrieved 2026-10-18.
2. Korus S, Cembrowska-Lech D, Kłoda K, Stachowska E. Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists — preliminary study. Journal of Translational Medicine, 2026;24:532. doi:10.1186/s12967-026-07702-4
3. European Medicines Agency. Saxenda (liraglutide) — Summary of Product Characteristics and Package Leaflet, Annex I and Annex IIIB. First authorisation 23 March 2015. Sections 4.4, 4.8 and 5.1. Retrieved 2026-10-18.
4. European Medicines Agency. Mounjaro (tirzepatide) — Summary of Product Characteristics, Annex I. First authorisation 15 September 2022. Sections 4.4 and 4.8. Retrieved 2026-10-18.